Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

First of all you did not provide any

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
MedResCollab Member Profile
 
Followed By 2
Posts 211
Boards Moderated 0
Alias Born 01/18/19
160x600 placeholder
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Pot... GlobeNewswire Inc. - 5/15/2021 8:00:00 AM
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Present... GlobeNewswire Inc. - 5/4/2021 7:00:00 AM
Amarin reports decline in Q1 revenue ahead of European launch of VAZKEPA Seeking Alpha - 4/29/2021 7:31:32 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/29/2021 6:36:55 AM
Amarin EPS beats by $0.07, misses on revenue Seeking Alpha - 4/29/2021 6:16:54 AM
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 4/29/2021 6:10:00 AM
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel GlobeNewswire Inc. - 4/29/2021 6:00:00 AM
Amarin Q1 2021 Earnings Preview Seeking Alpha - 4/28/2021 1:06:54 PM
UK approves Amarin's Vazkepa for cardiovascular risk reduction Seeking Alpha - 4/22/2021 11:22:31 AM
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agenc... GlobeNewswire Inc. - 4/22/2021 10:53:02 AM
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 GlobeNewswire Inc. - 4/20/2021 6:05:00 AM
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Present... GlobeNewswire Inc. - 4/17/2021 9:50:00 AM
Amarin: Could the New CEO Help Vazkepa’s European Push? TipRanks - 4/13/2021 3:05:37 PM
Amarin falls as new CEO may mean M&A less likely in the near term Seeking Alpha - 4/13/2021 8:08:18 AM
Amarin CEO John Thero to retire Seeking Alpha - 4/12/2021 4:36:21 PM
Amarin Announces CEO Succession Plan GlobeNewswire Inc. - 4/12/2021 4:30:00 PM
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular... GlobeNewswire Inc. - 4/6/2021 6:05:00 AM
Amarin wins EU approval for icosapent ethyl to treat cardiovascular patients Seeking Alpha - 3/30/2021 7:42:41 AM
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk GlobeNewswire Inc. - 3/30/2021 6:24:23 AM
Amarin announces clinical recommendations for Vascepa in Canada and Egypt Seeking Alpha - 3/29/2021 10:33:15 AM
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is R... GlobeNewswire Inc. - 3/29/2021 7:00:00 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
HLS Therapeutics highlights promising VASCEPA data analysis Seeking Alpha - 3/17/2021 11:55:39 AM
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in... GlobeNewswire Inc. - 3/17/2021 11:30:00 AM
Amarin Q4 results led by strong Vascepa sales Seeking Alpha - 2/25/2021 9:48:43 AM
MedResCollab   Wednesday, 07/10/19 10:57:06 AM
Re: HDGabor post# 200775
Post # of 339968 
Quote:
First of all you did not provide any evidence … just your view / interpretation of available info.

The counter-arguments will be the real evidences as:
- no AdCom
- FDA approval
- settlement with ANDAs or the favorable court decision

If all these in the bags: will you think you were wrong or it will means everybody were wrong and ignored the "evidences" provided by you? ... -HDGabor



You assert we presented no evidence that the REDUCE-IT results may have been confounded by the inhibition of cardiac medications in the placebo group?

Quote:
ev·i·dence
/'ev?d?ns/
noun
noun: evidence
1. the available body of facts or information indicating whether a belief or proposition is true or valid.



Our 82-page CP if filled with information indicating cardiac medications were attenuated in the mineral oil placebo group in REDUCE-IT. What do you mean, "no evidence?"

https://www.regulations.gov/document?D=FDA-2019-P-3156-0001

Currently we are in a phase of probability known as "handicapping." Given the totality of information available, what are the odds of:

-sNDA approval
-no AC meeting
-no clinical hold on EVAPORATE
-no extension of PDUFA date
-settlement of patent litigation cases
-win in patent litigations late Jan/early Feb

Our evidence suggests that the odds of the above are much less favorable to AMRN than the market believes, giving AMRN an inflated (in our view) $7B+ market cap.

Whether we are wrong ultimately is a difficult matter to resolve. That may seem like scapegoating, but it is not. Consider that we are all predicting the likelihood of an event(s). Any prediction has odds. All outcomes are absolute, regardless of the previous odds. If you were given 3:1 return on a proposition that had a 50% chance of occurring, you have a positive ROI if you take it. The outcome does not determine whether your "call" was right or wrong.

Of course, anyone can say after the fact, "I should have bet everything on it!" or, "I should never have bet even $1!" But that is irrelevant to the correctness of the call.

Regards,
-MRC


...
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences